1. Home
  2. AIOT vs CRBP Comparison

AIOT vs CRBP Comparison

Compare AIOT & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PowerFleet Inc.

AIOT

PowerFleet Inc.

N/A

Current Price

$2.86

Market Cap

683.8M

ML Signal

N/A

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$8.41

Market Cap

134.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIOT
CRBP
Founded
1993
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.8M
134.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
AIOT
CRBP
Price
$2.86
$8.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$10.33
$45.60
AVG Volume (30 Days)
1.5M
191.4K
Earning Date
02-09-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
$24.46
N/A
Revenue Next Year
$9.01
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
97.62
52 Week Low
$2.78
$4.64
52 Week High
$6.38
$20.56

Technical Indicators

Market Signals
Indicator
AIOT
CRBP
Relative Strength Index (RSI) 29.08 45.62
Support Level N/A $7.45
Resistance Level $5.62 $8.63
Average True Range (ATR) 0.16 0.66
MACD 0.01 -0.11
Stochastic Oscillator 14.53 25.09

Price Performance

Historical Comparison
AIOT
CRBP

About AIOT PowerFleet Inc.

PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: